Biogen Idec Oral MS Agent BG-12 Safety Takes Center Stage At Firm’s R&D Day
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryBiogen Idec highlighted the safety profile of its oral multiple sclerosis compound BG-12 during its recent R&D Day.
You may also be interested in...
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.